Payment overview · 2025
General Payments
$502.29
28 reported records · 13 companies
Healthcare provider profile · identity verified
William D Adams, DO
Allopathic & Osteopathic Physicians|Family Medicine · RIGBY, ID · NPI 1467403733
Verified facts
What the public records show
CMS Open Payments records show William D Adams, DO received $502.29 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.50 | 30.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.08 | 12.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.98 | 7.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.92 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.16 | 6.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.91 | 6.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.82 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.06 | 5.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.00 | 4.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.19 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.39 | 3.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.20 | 3.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.08 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.29 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.98 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.52 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.52 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.08 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.08 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.92 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 338 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 229 | 70 |
| Metformin Hcl | Metformin Hcl | 224 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 43 |
| Prednisone | Prednisone | 167 | 95 |
| Furosemide | Furosemide | 160 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 39 |
| Simvastatin | Simvastatin | 144 | 47 |
| Losartan Potassium | Losartan Potassium | 131 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 41 |
| Lisinopril | Lisinopril | 129 | 44 |
| Azithromycin | Azithromycin | 122 | 81 |
| Eliquis | Apixaban | 120 | 27 |
| Potassium Chloride | Potassium Chloride | 120 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 34 |
| Gabapentin | Gabapentin | 116 | 35 |
| Trazodone Hcl | Trazodone Hcl | 116 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 29 |
| Sertraline Hcl | Sertraline Hcl | 100 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 20 |
| Pregabalin | Pregabalin | 89 | 23 |
| Clonazepam | Clonazepam | 80 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 28 |
| Alprazolam | Alprazolam | 76 | 13 |
| Meloxicam | Meloxicam | 76 | 22 |
| Alendronate Sodium | Alendronate Sodium | 75 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 17 |
| Carvedilol | Carvedilol | 72 | 25 |
| Montelukast Sodium | Montelukast Sodium | 71 | 14 |
| Tramadol Hcl | Tramadol Hcl | 71 | 25 |
| Celecoxib | Celecoxib | 69 | 23 |
| Memantine Hcl | Memantine Hcl | 67 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 20 |
| Glipizide | Glipizide | 60 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 17 |
| Allopurinol | Allopurinol | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 20 |
| Propranolol Hcl | Propranolol Hcl | 53 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 17 |
| Cephalexin | Cephalexin | 47 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 17 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Naproxen | Naproxen | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 26 |
| Atenolol | Atenolol | 35 | 11 |
| Temazepam | Temazepam | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.29 · 28 records | ABBVIE INC. | AIRSUPRA, Auvelity, ELIQUIS, GEMTESA, General - Pain Management, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, ULTOMIRIS, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error